<SEC-DOCUMENT>0001140361-24-036283.txt : 20240808
<SEC-HEADER>0001140361-24-036283.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808072104
ACCESSION NUMBER:		0001140361-24-036283
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240808
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Holdings plc
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39992
		FILM NUMBER:		241186046

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immunocore Ltd
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20033789_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:imcr="http://immunocore.com./20240808" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using Broadridge PROfile 24.6.2.5244
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_9182d3cddd904cf98e39820bbb07a112" contextRef="c20240808to20240808" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_bd98693d0b7c4e30860edbad8272d2d1" contextRef="c20240808to20240808">0001671927</ix:nonNumeric><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_e50e23c8fe0f4bfebb8babfb04b35d3e" contextRef="c20240808to20240808">00-0000000</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="imcr-20240808.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240808to20240808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671927</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-08</xbrli:startDate><xbrli:endDate>2024-08-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
  <div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_5f88e26441fd4e7f8c0dee7bcf19d430" contextRef="c20240808to20240808">8-K</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span></div>

      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of the Securities Exchange Act of 1934</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_1d1db6e510014e1e8cffec9223f83b08" contextRef="c20240808to20240808" format="ixt:date-monthname-day-year-en">August 8, 2024</ix:nonNumeric></div>

    <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
    </div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_c9200b9e712b4941aa48ed5ed31febd0" contextRef="c20240808to20240808">Immunocore Holdings plc</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its Charter)</div>

    <div style="text-align: center;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    <div> <br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_e2ee9f77ec844cb4837a0d2b990c4822" contextRef="c20240808to20240808" format="ixt-sec:edgarprovcountryen">England and Wales</ix:nonNumeric><br/>
              </span></div>
          </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_7c6b857bba974b52ab156471d5f3b988" contextRef="c20240808to20240808">001-39992</ix:nonNumeric><br/>
              </span></div>
          </td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;"><span style="-sec-ix-hidden:Fact_e50e23c8fe0f4bfebb8babfb04b35d3e">Not Applicable</span><br/>
              </span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(State or other jurisdiction of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Commission File Number)</div>
          </td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_5d89465973714ad48ac5100d18649163" contextRef="c20240808to20240808">92 Park Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_7178df4025804e72a22f647d2b2e8fa0" contextRef="c20240808to20240808">Milton Park</ix:nonNumeric></div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine3" id="Fact_94fc2fea0902488489b8f628339812e8" contextRef="c20240808to20240808">Abingdon</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_eb44ec49a58f4390af79d1faf41cbf14" contextRef="c20240808to20240808">Oxfordshire</ix:nonNumeric>,</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCountry" id="Fact_d2ef7854c3a14a2fa3b9730099c77d5a" contextRef="c20240808to20240808" format="ixt-sec:countrynameen">United Kingdom</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_36c3b00f7cbb491a84fda88136952c40" contextRef="c20240808to20240808">OX14 4RY</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Address of principal executive offices)</div>
          </td>

    <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">+<ix:nonNumeric name="dei:CityAreaCode" id="Fact_b5a8419cb3084866a7f8bc5f0ff7832d" contextRef="c20240808to20240808">44</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_00cd578201274fd09ae5c2b1d71c68b4" contextRef="c20240808to20240808">1235 438600</ix:nonNumeric></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Registrant&#8217;s telephone number, including area code)</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Not Applicable</div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Former name or former address, if changed since last report)</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/>
    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
      following provisions:</div>

    <div><span style="font-size: 10pt;"><br/>
    </span></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_0251b943961642c0808f70d74047ec12" contextRef="c20240808to20240808" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_5030b042c9e84672bb8f3adee8b0bbda" contextRef="c20240808to20240808" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_c2a01de1cd694081bdcb96c662a4f20e" contextRef="c20240808to20240808" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
          </td>

  </tr>


</table>
    <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_484cf9a4fbee425d82adcea86ac8e104" contextRef="c20240808to20240808" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
          </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 55%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Title of each class</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Trading</div>
            <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Symbol(s)</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 55%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_76a07c9d81df49b2af396cc30862c718" contextRef="c20240808to20240808">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; text-align: center;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_1fdc6342bec147dfbe1a3087faba9c11" contextRef="c20240808to20240808">IMCR</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 1%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; text-align: center;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_3a911b3b84df42f199e0aa19ded07235" contextRef="c20240808to20240808" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 55%; vertical-align: top; font-size: 10pt; text-align: center;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Ordinary share, nominal value &#163;0.002 per share*</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 10%; vertical-align: top; font-size: 10pt; text-align: center;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">*</div>
          </td>

    <td style="width: 1%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

    <td style="width: 33%; vertical-align: top; font-size: 10pt; text-align: center;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">The Nasdaq Stock Market LLC</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">* <span style="font-family: 'Times New Roman'; font-style: italic;">Not for trading, but only in connection with the listing of the American Depositary
        Shares on The Nasdaq Stock Market LLC.</span></div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter)
      or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: right; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_f0c18f62725440688595266df8604f02" contextRef="c20240808to20240808" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
      revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 2.02.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Results of Operations and Financial Condition.</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; text-indent: 18pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On August 8, 2024, Immunocore Holdings plc (the &#8220;Company&#8221;) issued a press release announcing its financial results for the second quarter
      ended June 30, 2024, as well as other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; text-indent: 18pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The information in this Item 2.02 of this Current Report on 8-K, including Exhibits 99.1 hereto, is being furnished and shall not be
      deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company&#8217;s
      filings under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by
      specific references in such filing.</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01.</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Financial Statements and Exhibits</div>
          </td>

  </tr>


</table>
    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td colspan="1" style="width: 1%; vertical-align: bottom; font-size: 10pt;"><br/>
          </td>

    <td style="width: 12%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
          </td>

    <td style="width: 87%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
          </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt;"><br/>
          </td>

    <td style="width: 12%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 238); font-family: 'Times New Roman';"><a href="ef20033789-ex99-1.htm">99.1</a></div>
          </td>

    <td style="width: 87%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Press Release dated August 8, 2024.</div>
          </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 1%; vertical-align: top; font-size: 10pt;"><br/>
          </td>

    <td style="width: 12%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">104</div>
          </td>

    <td style="width: 87%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div> <br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURES</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by
      the undersigned hereunto duly authorized.</div>

    <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> </span><span style="font-size: 10pt;"><br/>
      </span></div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="4">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">IMMUNOCORE HOLDINGS PLC</div>
          </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: middle; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: middle; font-size: 10pt;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Dated: August 8, 2024</div>
          </td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">By:</div>
          </td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">/s/ Bahija Jallal, Ph.D.</div>
          </td>

    <td style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 8%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name:</div>
          </td>

    <td style="width: 45%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Bahija Jallal, Ph.D.</div>
          </td>

    <td style="width: 7%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 8%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title:</div>
          </td>

    <td style="width: 45%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Chief Executive Officer</div>
          </td>

    <td style="width: 7%; vertical-align: bottom; font-size: 10pt;">&#160;</td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20033789-ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using Broadridge PROfile 24.6.2.5244
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div style="width: 100%;" class="BRPFPageHeader"></div>
  <font style="font-size: 10pt;"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Exhibit 99.1</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <div style="font-size: 10pt;"><img src="image00005.jpg"></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore reports second quarter financial results and provides a business update</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; margin-left: 3.3pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; margin-left: 3.3pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma ongoing,
        following conversion of Phase 2/3 trial &#8211; expect to complete enrollment in 1H 2026</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; margin-left: 3.3pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Registrational Phase 3 (PRISM-MEL-301) evaluating brenetafusp + nivolumab in first-line cutaneous melanoma
        started randomization</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; margin-left: 3.3pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Presented Phase 1 data of brenetafusp in late-line cutaneous melanoma patients at ASCO 2024; late-line
        high-grade serous ovarian data to be presented at ESMO 2024</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Conference call today, August 8, 2024 at 8:00 AM ET, 1:00 PM BST</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">OXFORDSHIRE, England &amp; CONSHOHOCKEN, Penn. &amp; ROCKVILLE, Md., US</font>, 08 August 2024) <u><font style="font-family: 'Times New Roman';">Immunocore Holdings plc (Nasdaq: IMCR) (&#8220;Immunocore&#8221; or the &#8220;Company&#8221;)</font></u><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, a </font>commercial-stage biotechnology company
        pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the second quarter ended June 30,
        2024 and provided a business update.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;Over the next 18 months, we will present multiple data read-outs including brenetafusp and the HIV MAD data, while progressing three Phase 3 trials, with
        registrational data expected in 2026, 2027 and 2028. We will also advance our new autoimmune and oncology clinical and pre-clinical programs,&#8221; said <font style="font-family: 'Times New Roman'; font-weight: bold;">Bahija Jallal, Chief Executive
          Officer of Immunocore.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;In the first half of 2024, we expanded KIMMTRAK&#8217;s reach in the US community setting and globally with 9 new launches and 2 additional reimbursement agreements, in the
        context of a challenging market access environment in Europe,&#8221; <font style="font-family: 'Times New Roman'; font-weight: bold;">said Ralph Torbay, Immunocore&#8217;s Chief Commercial Officer.</font> &#8220;We are exploring the potential of KIMMTRAK to benefit
        more patients and deliver revenue growth beyond metastatic uveal melanoma with our two ongoing Phase 3 registrational trials in previously treated cutaneous melanoma and in adjuvant uveal melanoma.&#8221;</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>1<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Second Quarter 2024 Highlights (including post-period)</div>
      <div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">KIMMTRAK</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company&#8217;s lead product, KIMMTRAK, is approved in 38 countries and has been launched in 19 countries globally to date for HLA-A*02:01 positive
          patients with unresectable or metastatic uveal melanoma (mUM). KIMMTRAK continues to be the standard of care in most markets where it is launched. The Company sees three key growth areas for the KIMMTRAK opportunity, including: continued global
          expansion in mUM, as well as the potential expansion into 2L+ advanced cutaneous melanoma (CM) and adjuvant uveal melanoma.</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Metastatic uveal melanoma</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z19b7c5df4f8448138c9dc2b9b6b57d55" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">In Q2 2024, KIMMTRAK net product sales were $75 million and $146 million for the three and six months ended June 30, respectively, representing increases of 32% and 34% respectively, compared to
                  the prior year periods.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z91c7cc4671a14ab7a99097bb2cf74cd7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">US growth driven by increased penetration in community setting and duration of treatment.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z5d833112ce1f4c98ad2bc01920e08c8b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">As of July 1, 2024, KIMMTRAK is launched in 19 countries. Reimbursement agreements reached in Sweden and Poland with expected launches in second half of 2024.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z2de3baf9567940ffa7ec5cded4fd4bc5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Published data at ASCO 2024 demonstrating that KIMMTRAK-treated mUM patients with stable disease and any confirmed tumor reduction have similar clinical outcomes to patients with RECIST partial
                  response.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z1c2bc1ee38c74db2a02cb918315b7862" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">New T cell fitness insights from the Phase 2 KIMMTRAK trial in previously treated uveal melanoma will be an oral presentation during the &#8220;Basic Science &amp; Translational Research&#8221; proffered
                  session at the 2024 ESMO Congress.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">2L + Previously treated cutaneous melanoma</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z8c337c66d4d8499e88cf9863c5429cfe" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Converted Phase 2/3 TEBE-AM trial into registrational Phase 3 trial, which will continue three arms: KIMMTRAK monotherapy, KIMMTRAK in combination with pembrolizumab, and control.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z08dadc0c25814b2abc5c75ecca4572ac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Over 120 patients already randomized into the original Phase 2 portion will now be included in the Phase 3 trial, which we expect will accelerate time to final endpoint by up to 12 months.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z19702c19c90240d98e084605f44ee6ff" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Expect enrollment to be completed in the first half of 2026.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Adjuvant uveal (or ocular) melanoma</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z71a5bc4871cd4dd8aaaf6fff530dc3db" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Randomization in the ATOM Phase 3 trial, led by the European Organisation for Research and Treatment of Cancer (EORTC), expected to start in the second half of 2024.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PRAME franchise</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Brenetafusp (IMC-F106C) is the Company&#8217;s lead PRAME-A02 ImmTAC bispecific candidate.&#160; Brenetafusp is being evaluated in combination with nivolumab,
          in a Phase 3 registrational trial (PRISM-MEL-301) in patients with first-line advanced cutaneous melanoma (CM) and in a Phase 1/2 clinical trial, as monotherapy and in combination, across multiple tumor types, including platinum resistant
          ovarian, non-small cell lung (NSCLC), and endometrial carcinoma.</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>2<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">PRISM-MEL-301 &#8211; First PRAME Phase 3 clinical trial with brenetafusp in first-line advanced or metastatic HLA-A*02:01 positive
          cutaneous melanoma</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z0ba6840c841040d285c430f38cf5a09e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">In 2Q, the Company randomized the first patient in PRISM-MEL-301.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z8335dc24d3cb4f328bab438348574138" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Trial is evaluating brenetafusp + nivolumab versus a control arm of either nivolumab or nivolumab + relatlimab.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1/2 clinical trial of brenetafusp (PRAME-A02) in multiple solid tumors</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z34ff6b1ea4e541d694f79bdb67be0a0c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Presented data at ASCO 2024 from the Phase 1/2 trial with brenetafusp in patients with late-line CM showing promising brenetafusp monotherapy disease control (partial response and stable
                  disease), progression free survival (PFS), and circulating tumor DNA (ctDNA) molecular response. In PRAME positive patients, the disease control rate was 58% and median PFS was 4.2 months. Brenetafusp was well tolerated as monotherapy and
                  in combination with anti-PD1.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="zb4d731c21c4f42979d45a1cadf8ddc73" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Clinical data from monotherapy and chemotherapy combinations in heavily pre-treated platinum-resistant high grade serous ovarian cancer will be presented as a poster at ESMO 2024 (Phase 1 safety
                  and efficacy of brenetafusp, a PRAME &#215; CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC), Poster 750P). The next step is to further evaluate brenetafusp in combination with non-platinum chemotherapies in platinum
                  resistant disease and to test the combination with platinum chemotherapy and with bevacizumab in platinum sensitive disease.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z66ceb1cb4c084072b0378d47a37879e3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">The Company plans to present clinical data for brenetafusp in late-line non-small cell lung cancer (NSCLC) in the fourth quarter of 2024. The next step is to evaluate brenetafusp in combinations
                  with docetaxel and with osimertinib in earlier-line NSCLC.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-P115C (PRAME-A02 Half-Life Extended) &amp; IMC-T119C (PRAME-A24)</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z7a6b56ef8d08455c9bb5cac952519d98" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Submitted Clinical Trial Application (CTA) for IMC-P115C in the second quarter of 2024, which is currently under review.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z0fead8c66eaf4fb4a44658b0f36944f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Remain on track for regulatory submission of Investigational New Drug (IND) or Clinical Trial Application (CTA) for IMC-T119C in the fourth quarter of 2024.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additional Oncology Candidates</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-R117C (first PIWIL1-A02 targeted immunotherapy) for colorectal and other gastrointestinal cancers</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company has leveraged its proprietary peptidomic database to validate a novel target, PIWIL1. PIWIL1 is a negative prognostic marker and is
          expressed across a range of tumors including colorectal, which is historically insensitive to immune checkpoints, as well as gastro-esophageal, and pancreatic cancer.</div>
      </div>
      <div style="font-size: 10pt;">
        <div><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z407ace4eb32c4e9185ad9b7c192cbca6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">The CTA for IMC-R117C was accepted in April 2024 by the EMA, and the Phase 1 clinical trial is expected to start in the second half of 2024.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>3<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ImmTAV Candidates for a Functional Cure in Infectious Diseases</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company&#8217;s bispecific TCR technology platform has potential to offer a new approach for the treatment of chronic infections and aims to eliminate
          evidence of remaining virus in circulation after the patient stops taking medication - known as a "functional cure". Two investigational candidates are in Phase 1 clinical trials for people living with human immunodeficiency virus (HIV) and
          people with chronic Hepatitis B infection (HBV).</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1 trial of IMC-M113V (Gag-A02) for people living with HIV</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z2a6229570ca14687a50e31ff2492fca0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">The objective of the clinical trial is to identify a safe and tolerable dose and evaluate whether IMC-M113V could lead to reduction in the viral reservoir and, after stopping antiretroviral
                  therapies (ART) and IMC-M113V, delay or prevent HIV rebound.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="zf8cfed9181dd4550a2c155ce55487104" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Historically, viral rebound occurs rapidly after ART interruption at a median of 2 weeks, and approximately 98% of people will have &gt;200 viral copies/ml (the threshold for transmission) by
                  week 8 (Feher C et. al, 2019).</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="ze9e8fcdf1a644876ab361a5ebaf357c2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">In the MAD portion, the Company has enrolled 3 cohorts with 5 people living with HIV (PLWH) per cohort. The highest tested dose is 300 mcg.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z38e702faa36b409eb2963da17294b3a8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">A biologically active dose has been reached and the Company plans to enroll more (PLWH) to characterize anti-viral activity and to explore higher doses. This will move the planned data release
                  from fourth quarter of 2024 into first quarter of 2025.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Phase 1 trial of IMC-I109V (Envelope-A02) for people living with HBV or HBV-positive hepatocellular carcinoma</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z7a9592940bd642fc98a26d0f5e8e7e80" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">Patient enrollment continues into the single ascending dose portion of the clinical trial.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Tissue-specific Down Modulation of the Immune System for Autoimmune Diseases</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">The Company is expanding its platform into autoimmune diseases with two new, first-in-class bispecific candidates recently entering its pipeline.
          The key differentiator of the Company&#8217;s ImmTAAI (Immune Modulating Monoclonal TCRs Against AutoImmune disease) platform is tissue-specific down modulation of the immune system whereby, when tethered to the tissue of interest, the new candidates
          suppress pathogenic T cells via PD1 receptor agonism.</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>4<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">IMC-S118AI (pre-pro insulin A02 x PD1), intended for disease-modifying treatment in type 1 diabetes</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="ze07fa9f20e57454baa9d411559dbb0f5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">IMC-S118AI recognizes a peptide from pre-proinsulin presented by HLA-A02 on beta cells, coupled with a PD1 agonist effector arm.</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" id="z9f9d3d3316da4dc690ea10a21eee23f5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">IMC-S118AI is advancing towards GMP manufacturing in 2024.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Undisclosed non-HLA restricted (universal) candidate for inflammatory dermatological diseases</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z8317fc680b4543ff96148cc24e0ab359" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; font-size: 10pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
                <div style="font-family: 'Times New Roman';">The candidate is an antigen presenting cell (APC) tethered ImmTAAI and is not HLA restricted (i.e. universal for all populations).</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">
        <div><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ESMO Congress 2024 - Presentation and poster details</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; margin-left: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Title: </font><font style="font-size: 10pt;">Phase 1 safety and
            efficacy of brenetafusp, a PRAME &#215; CD3 ImmTAC T cell engager, in platinum resistant ovarian cancer (PROC) (Poster 750P)</font></div>
      </div>
      <div>
        <div style="text-align: left; text-indent: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Presenting author: </font><font style="font-size: 10pt;">Claire
            F. Friedman</font></div>
      </div>
      <div>
        <div style="text-align: left; margin-left: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Session: </font><font style="font-size: 10pt;">Poster Session &#8211;<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Gynaecological cancers, Saturday 14 September 2024; 09:00 a.m. - 5:00 p.m. CEST / 04:00 a.m. - 12:00 p.m. ET</font></div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; margin-left: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Title: </font><font style="font-size: 10pt;">Chemotherapy and
            hypomethylating agents enhance anti-tumor activity of PRAME ImmTAC</font></div>
      </div>
      <div>
        <div style="text-align: left; text-indent: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Presenting author: </font><font style="font-size: 10pt;">Adel
            Benlahrech</font></div>
      </div>
      <div>
        <div style="text-align: left; margin-left: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Session: </font><font style="font-size: 10pt;">Poster Session &#8211;<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Investigational immunotherapy, Saturday 14 September 2024; 09:00 a.m. - 5:00 p.m. CEST / 04:00 a.m. - 12:00 p.m. ET (Poster 1021P)</font></div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <div style="text-align: justify; margin-left: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Title: </font><font style="font-size: 10pt;">Association of
            a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers (Oral 66O)</font></div>
        <div style="text-align: justify; margin-left: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Presenting author: </font><font style="font-size: 10pt;">Joseph






            Sacco</font></div>
      </div>
      <div>
        <div style="text-align: left; margin-left: 35.45pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Session: </font><font style="font-size: 10pt;">Proffered paper
            session 2 &#8211; Basic Science and Translational Research, Monday 16 September 2024; 02:45-04:15 p.m. CEST / 09:45-11:15 a.m. ET</font></div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Financial Results</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For the second quarter ended June 30, 2024, the Company generated net product sales of $75.3 million compared to $56.9 million for the same period in 2023. This
          increase was due to revenue from KIMMTRAK, of which $55.6 million was in the United States, $15.4 million (net of an increase in estimated reserves related to prior periods of $6.7 million) in Europe, and $4.3 million in international regions.
          The increase in net product sales was due primarily to increased volume in the United States and global country expansion, as the Company continued its commercialization efforts.</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For the second quarter ended June 30, 2024, research and development (R&amp;D) expenses were $51.1 million, compared to $38.2 million for the same period in 2023. This
          increase was primarily driven by expenses incurred for the PRAME programs, including the initiation of the Company&#8217;s Phase 3 clinical trial.</div>
        <div style="font-size: 10pt;"><br>
        </div>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>5<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">For the quarter ended June 30, 2024, SG&amp;A expenses were $38.6 million, compared to $35.0 million for the same period in 2023. This increase was primarily related to
          additional employees engaged in business support functions, including medical and regulatory activities, to support our growing pipeline and commercial activities.</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Basic and diluted loss per share was $0.23 for the quarter ended June 30, 2024, as compared to a basic and diluted loss per share of $0.35 for the same period in 2023.
          Net loss for the quarter ended June 30, 2024 was $11.6 million, as compared to $17.0 million for the same period in 2023.</div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cash, cash equivalents, and marketable securities at June 30, 2024 were $859.6 million. The Company plans to use $50 million to repay its existing loan by the end of
          2024, and also expects to pay approximately $40 million in sales-related rebate accruals in the second half of 2024.</div>
      </div>
      <div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About ImmTAC<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> molecules for cancer</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore&#8217;s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against
        Cancer) molecules that are designed to redirect the immune system to recognize and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these
        cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of
        mutational burden or immune infiltration, including immune &#8220;cold&#8221; low mutation rate tumors.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About ImmTAV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> molecules and infectious diseases</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">ImmTAV (Immune mobilizing monoclonal TCRs Against Virus) molecules are novel bispecifics that are designed to enable the immune system to recognize and eliminate
        virally infected cells. Immunocore is advancing clinical candidates to achieve functional cure for patients with HIV and hepatitis B virus (HBV). The Company aims to achieve sustained control of HIV after patients stop anti-retroviral therapy
        (ART), without the risk of virological relapse or onward transmission. This is known as &#8216;functional cure&#8217;. For the treatment of HBV, the Company aims to achieve sustained loss of circulating viral antigens and markers of viral replication after
        stopping medication for people living with chronic HBV.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>6<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About ImmTAAI<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> molecules and autoimmune diseases</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">ImmTAAI (Immune mobilizing monoclonal TCRs Against AutoImmune disease) molecules are novel bispecifics that are designed for tissue-specific down modulation of the
        immune system. When tethered to the tissue of interest, ImmTAAI candidates suppress pathogenic T cells via PD1 receptor agonism. The Company is currently advancing two candidates for autoimmune diseases, including type 1 diabetes and inflammatory
        dermatological diseases.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About PRISM-MEL-301 (NCT06112314) &#8211; Phase 3 trial with brenetafusp (IMC-F106C, PRAME-A02) in 1L advanced cutaneous melanoma</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Phase 3 registrational trial is randomizing HLA-A*02:01-positive patients with previously untreated advanced melanoma to brenetafusp + nivolumab versus nivolumab
        or nivolumab + relatlimab, depending on the country where the patient is enrolled. The trial will initially randomize to three arms: two brenetafusp dose regimens (40 mcg and 160 mcg) and a control arm. One of the two brenetafusp dose regimens will
        be discontinued after an initial review of the first 60 patients randomized to the two experimental arms (90 patients randomized total). The primary endpoint of the trial is progression free survival (PFS) by blinded independent central review
        (BICR), with secondary endpoints of overall survival (OS) and overall response rate (ORR).</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About the IMC-F106C-101 Phase 1/2 trial</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">IMC-F106C-101 is a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumors, including non-small cell lung cancer (NSCLC), small-cell
        lung cancer (SCLC), endometrial, ovarian, cutaneous melanoma, and breast cancers. The Phase 1 dose escalation trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and
        pharmacokinetics of IMC-F106C (brenetafusp), a bispecific protein built on Immunocore&#8217;s ImmTAC technology, and the Company&#8217;s first molecule to target the PRAME antigen. The Company is enrolling patients into three expansion arms in NSCLC, as well
        as ovarian and endometrial carcinomas. The IMC-F106C-101 trial is adaptive and includes the option for Phase 2 expansion, allowing for approximately 100 patients treated per tumor type in the Phase 1 and 2 expansion arms. Dose escalation continues
        in additional solid tumors as well as plans for combination arms with standards-of-care, including checkpoint inhibitors, chemotherapy, and tebentafusp.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About TEBE-AM &#8211; Phase 3 registrational trial with tebentafusp in previously treated advanced cutaneous melanoma</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The trial is randomizing patients with second-line or later advanced cutaneous melanoma who have progressed on an anti-PD1, received prior ipilimumab and, if
        applicable, received a BRAF kinase inhibitor. Patients are randomized to one of three arms, including tebentafusp &#8211; as monotherapy or in combination with an anti-PD1 &#8211; or a control arm. The primary endpoint is overall survival.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>7<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About the ATOM Phase 3 trial</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The EORTC-led Phase 3 clinical trial will include sites in 10 EU countries and the United States and will randomize HLA-A*02:01-positive patients with high-risk
        primary uveal melanoma after definitive treatment, by surgery or radiotherapy, and no evidence of metastatic disease on imaging. The trial is expected to enroll a total of 290 patients who will be randomized 1:1 to one of two arms: tebentafusp as
        monotherapy or observation. The primary endpoint of the trial is relapse-free survival (RFS), with secondary objectives of overall survival and safety and tolerability of tebentafusp. Exploratory objectives include comparison of health-related
        quality of life between the treatment arms and evaluation of the role of circulating tumor DNA (ctDNA) as a biomarker for the presence of residual disease.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About Uveal Melanoma</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Uveal melanoma is a rare and aggressive form of melanoma affecting the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis is
        rare, and up to 50% of people with uveal melanoma will eventually develop metastatic disease. Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About Cutaneous Melanoma</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Cutaneous melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer-related
        mortality. The majority of patients with CM are diagnosed before metastasis but survival remains poor for the large proportion of patients with metastatic disease. Despite recent progress in advanced melanoma therapy, there is still an unmet need
        for new therapies that improve first-line response rates and duration of response as well as for patients who are refractory to first-line treatments.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About KIMMTRAK<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup></div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a
        lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore&#8217;s ImmTAC technology platform, designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has been approved for
        the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>8<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">IMPORTANT SAFETY INFORMATION</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred
          in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated.</font><font style="font-size: 10pt;"> Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea,
          vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK, with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients
          are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or
          discontinue KIMMTRAK depending on persistence and severity of CRS.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Skin Reactions</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions
        occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Elevated Liver Enzymes</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total
        blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Embryo-Fetal Toxicity</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during
        treatment with KIMMTRAK and 1 week after the last dose.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The most common adverse reactions (&#8805;30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal
        pain, edema, hypotension, dry skin, headache, and vomiting. The most common (&#8805;50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased
        phosphate.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS).</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>9<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">About KIMMTRAKConnect</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore is committed to helping patients who need KIMMTRAK obtain access via our KIMMTRAKConnect program. The program provides services with dedicated nurse case
        managers who provide personalized support, including educational resources, financial assistance, and site of care coordination. To learn more, visit KIMMTRAKConnect.com or call 844-775-2273.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">About Immunocore</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; Immune mobilizing
        monoclonal TCRs Against X disease &#8211; designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep
        pipeline in multiple therapeutic areas, including nine active clinical and pre-clinical programs&#8203; in oncology, infectious diseases, and autoimmune diseases. The Company&#8217;s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the
        treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>10<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Forward Looking Statements</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
        Words such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221; and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements,
        other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the commercial performance of KIMMTRAK; the potential benefits and
        advantages that KIMMTRAK will provide for patients, including its potential for expansion into other indications such as cutaneous and adjuvant uveal melanoma; expectations regarding the design, progress, timing, enrollment, randomization, scope,
        expansion, funding, and results of the Company&#8217;s existing and planned clinical trials; the timing and sufficiency of clinical trial outcomes to support potential approval of any of the Company&#8217;s product candidates or those of, or combined with, its
        collaboration partners; the Company&#8217;s goals to develop and commercialize product candidates based on its KIMMTRAK platform alone or with collaboration partners; the expected submission of investigational new drug applications or clinical trial
        applications; the potential regulatory approval, expected clinical benefits and availability of the Company&#8217;s product candidates; and the use of the Company&#8217;s cash, cash equivalents and marketable securities. Any forward-looking statements are
        based on management&#8217;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such
        forward-looking statements, many of which are beyond the Company&#8217;s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company&#8217;s business, financial position, strategy and
        anticipated milestones, including Immunocore&#8217;s ability to conduct ongoing and planned clinical trials; Immunocore&#8217;s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved
        products; Immunocore&#8217;s ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore&#8217;s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch,
        market and sell KIMMTRAK and any future approved products; Immunocore&#8217;s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current
        or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore&#8217;s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if
        at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical
        trials or future regulatory approval; Immunocore&#8217;s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and
        unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict between Hamas and Israel, and global geopolitical tension; Immunocore&#8217;s ability to obtain, maintain and enforce intellectual property protection for
        KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore&#8217;s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in
        greater detail in the section titled "Risk Factors" in Immunocore&#8217;s filings with the Securities and Exchange Commission, including Immunocore&#8217;s most recent Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities
        and Exchange Commission on February 28, 2024, as well as discussions of potential risks, uncertainties, and other important factors in the Company&#8217;s subsequent filings with the SEC. All information in this press release is as of the date of the
        release, and the Company undertakes no duty to update this information, except as required by law.</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Contact Information</div>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">S&#233;bastien Desprez, Head of Communications</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">T:<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font>+44 (0) 7458030732</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">E: <u><font style="font-family: 'Times New Roman';">sebastien.desprez@immunocore.com</font></u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Follow on Twitter: @Immunocore</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Investor Relations</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Clayton Robertson, Head of Investor Relations</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">T: +1 (215) 384-4781</div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">E: <u><font style="font-family: 'Times New Roman';">ir@immunocore.com</font></u></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>11<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div class="BRPFPageHeader" style="width: 100%;"></div>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Condensed Consolidated Statement of Operations</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Comparison of the Quarters and Year to Date Ended June 30, 2024 and 2023</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands, except share and per share data)</div>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z9cab116593e84e14be063710639f87d4" class="cfttable">

          <tr>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Quarter Ended</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt; border-bottom: #000000 solid 2px;" colspan="6">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Year to Date</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;"> June 30, 2024</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">June 30, 2023</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">June 30, 2024</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">June 30, 2023</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Product revenue, net</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman';">75,347</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">56,932</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman';">145,689</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">108,513</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; padding-bottom: 2px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Collaboration revenue</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman';">53</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">2,825</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="font-family: 'Times New Roman';">213</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">5,903</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Total revenue</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">75,400</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">59,757</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">145,902</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">114,416</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt; width: 52%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Cost of product revenue</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,707</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(346</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,953</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(562</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Research and development expense</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(51,072</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(38,158</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(108,531</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(74,730</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; padding-bottom: 2px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Selling, general, &amp; administrative expense</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(38,638</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(35,010</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(77,925</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(67,577</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Loss from operations</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(16,017</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(13,757</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(42,507</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(28,453</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Interest income</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">6,239</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">4,278</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">14,485</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">7,406</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Interest expense</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(4,277</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,274</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(7,516</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(2,524</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Foreign currency loss</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(508</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(5,880</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(2,914</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(11,893</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Other income (expense), net</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">4,433</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(190</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">4,243</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(515</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Net loss before income taxes</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(10,130</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(16,823</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(34,209</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(35,979</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Income tax expense</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,486</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(191</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(1,843</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(484</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; padding-bottom: 4px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Net loss</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(11,616</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(17,014</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(36,052</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(36,463</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; background-color: #CCEEFF;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Basic and diluted net loss per share</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(0.23</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(0.35</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(0.72</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">(0.75</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 52%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 52%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic;">Basic and diluted weighted average number of shares</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic;">50,014,086</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic;">48,694,047</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic;">49,944,767</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic;">48,440,318</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageFooter" style="width: 100%;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>12<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Condensed Consolidated Balance Sheets</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">As of June 30, 2024</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands)</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z53a8393876ed4b37a070bc91e4f8f86b" class="cfttable">

          <tr>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Jun '24</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Dec '23</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">ASSETS</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Current assets</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Cash and cash equivalents</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">504,985</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">442,626</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Marketable securities</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">354,612</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">-</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Accounts receivable, net</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">60,245</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">52,093</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Prepaid expenses and other current assets</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">33,555</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">29,600</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Inventory, net</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">3,462</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">4,501</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Total current assets</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">956,859</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">528,820</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Property and equipment, net</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">7,684</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">9,215</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Operating lease right of use assets, net</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">32,435</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">33,520</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Deferred tax assets, net</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">10,111</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">10,973</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; padding-bottom: 2px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Other non-current assets</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">16,276</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">14,473</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Total assets</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">1,023,365</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">597,001</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Liabilities and shareholders&#8217; equity</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Current liabilities</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Accounts payable</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">19,947</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">17,798</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Accrued expenses and other current liabilities</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">163,762</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">119,835</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Operating lease liabilities, current</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,387</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,388</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Total current liabilities</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">185,096</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">139,021</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Accrued expenses, non-current</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">2,089</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">978</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Deferred revenue, non-current</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">5,477</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">5,515</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Operating lease liabilities, non-current</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">33,445</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">34,633</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; padding-bottom: 2px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Interest-bearing loans and borrowings</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">438,121</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">48,011</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Total liabilities</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">664,228</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">228,158</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Shareholders' equity</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Ordinary shares</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">135</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">134</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Deferred shares</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Additional paid-in capital</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,174,147</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">1,149,643</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Accumulated deficit</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(780,726</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(744,674</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; padding-bottom: 2px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Accumulated other comprehensive loss</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(34,420</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(36,261</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Total shareholders' equity</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">359,137</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">368,843</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; padding-bottom: 4px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Total liabilities and shareholders' equity</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">1,023,365</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">597,001</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
                <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
                    </font></div>
                  <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>13<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
                </td>
              </tr>

          </table>
        </div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" class="BRPFPageHeader"></div>
      </div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Immunocore Holdings plc</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Summary Condensed Consolidated Statements of Cash Flows</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the Year to Date Period Ended June 30,</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(In thousands)</div>
      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Unaudited)</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z443710fde7704ecc935dffdf7c61d6fc" class="cfttable">

          <tr>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">June '24</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" style="font-size: 10pt; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">June '23</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt;">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: middle; font-size: 10pt;" colspan="2">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Cash and cash equivalents at beginning of period</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">442,626</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">402,472</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Net cash provided by operating activities</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">18,885</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">10,584</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Net cash used in investing activities</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(350,761</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(4,396</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Net cash provided by financing activities</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">395,194</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">17,716</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Net foreign exchange difference on cash held</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">(959</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftfncell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">)</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';">5,619</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: middle; font-size: 10pt; width: 76%; padding-bottom: 4px;">
              <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Cash and cash equivalents at end of period</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">504,985</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftfncell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">$</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">431,995</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
  </div>
  <div style="width: 100%;" class="BRPFPageFooter">
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;"><img src="image00001.jpg"></td>
          <td style="width: 50%; vertical-align: bottom; font-size: 10pt; text-align: right;">&#160;
            <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
              </font></div>
            <div style="color: rgb(0, 59, 127); font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <font style="color: rgb(0, 0, 0);">Page </font></font>14<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="color: rgb(0, 0, 0);"> of 14</font> </font></div>
          </td>
        </tr>

    </table>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>imcr-20240808.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.2.5244 Broadridge-->
<xs:schema targetNamespace="http://immunocore.com./20240808" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:imcr="http://immunocore.com./20240808" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20240808_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="imcr-20240808_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://immunocore.com./role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>imcr-20240808_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.2.5244 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>imcr-20240808_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.2.5244 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://immunocore.com./role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="imcr-20240808.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://immunocore.com./role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  ] 6X# 2(  A$! Q$!_\0
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M!G:S;L_6NDA3RXD0'(4 ?E3J*EMO<I)+8****0PHHHH **** "BBB@ HHHH
M9-&DT3QR*&1U*L#W!ZUS%IX+LHTMTNIIKI89'D <XW,0 N<?W5&!7544U)K8
M3BGN86C^'(-+FM7@FE9+6)X8D;D!&;./PZ"H[SPO;W,,R^<ZN]Y]M5]H.U\$
M8P1@C!/6NAHI\SO<7*K6. NO"E[#<K::=D6,C0-+(64 F,@DE=N0>. N!6FO
M@JU#1YNIO+2$PD!5#,"I7EL9Q@YQZUUE%-U)"Y$<U_PBL;6MQ'+>2O-+Y)$V
MQ05,6-IQC';I4;>$59),W\YEE,_FR;%^<2@;AC&!T&,5U-%+G8^1'*3>#8)5
MDB:[G^S$NZQ87"NV-S9QD_3IS6M8Z3]CU&>YBG?9.09(BHP2%51SU'W?UK5H
MH<F]P44CEY/!6E_:+B6V5[?SK62U*H<@!R26P>_-6/\ A'%-_!,]W,UO#*)U
M@*KCS NW.[&[')XS7044<\NX<J,>ZT**YEU-VFE!OD1&VX^0*.,?_7JC;^$K
M>*W1#<2F07/VEI$54)8(4  4 * #QCTKIJ*7,PY4<_:^&D0:@;N\N+F2]@^S
M.Y"H0F"/X0,MR?F/-5X?",:PS++>32/((4W!$0!(G#*,* "2>IZUU%%/G8<J
+"BBBI*"BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00005.jpg
<TEXT>
begin 644 image00005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  8 .<# 2(  A$! Q$!_\0
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M'WB/8-N['?&,UE2;5*\)<NK_ "1I-+VGOJ^AN0?!;0H95D76/$A*]FU#(_\
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;N_P__P! CQ+_ ."__P"RHHHK?ZA1,OK50__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139693027879200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  08,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunocore Holdings plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">92 Park Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Milton Park<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Abingdon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Oxfordshire<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX14 4RY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1235 438600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing one ordinary share, nominal value &#163;0.002 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMCR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MK4J+RY@S8',=X/E**?O6<%\2R@]!H_\ 4$L#!!0    ( *$Z"%F?H!OPL0(
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( *$Z"%D'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ H3H(632&2C+O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ H3H(69E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "A
M.@A9MABU<ZD$   4$@  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ H3H(69^@&_"Q @  X@P   T
M         ( ![0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "A.@A9EXJ[
M',     3 @  "P              @ ')#P  7W)E;',O+G)E;'-02P$"% ,4
M    " "A.@A9'#AEZC\!   \ @  #P              @ &R$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ H3H(620>FZ*M    ^ $  !H
M     ( !'A(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ H3H(6660>9(9 0  SP,  !,              ( ! Q,  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  310

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20033789_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immunocore.com./role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20033789_8k.htm">ef20033789_8k.htm</File>
    <File>imcr-20240808.xsd</File>
    <File>imcr-20240808_lab.xml</File>
    <File>imcr-20240808_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20033789_8k.htm": {
   "nsprefix": "imcr",
   "nsuri": "http://immunocore.com./20240808",
   "dts": {
    "inline": {
     "local": [
      "ef20033789_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "imcr-20240808.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "imcr-20240808_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "imcr-20240808_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://immunocore.com./role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240808to20240808",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20033789_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240808to20240808",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20033789_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://immunocore.com./role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001140361-24-036283-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-036283-xbrl.zip
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MTC<<-TB(<E-9J[C QTQGJ:7X,Z6!WV 6N&T+EI2<=W0:_$')/X'V:6B1XVG
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M\,.%9"1@":R'Q)(DGV>RGB%509YHCB'7C'U+A86'HZOOH"MG#!XP'/P5?U&
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M%OO+X_.4'$UH$,$!CIMP4IO20672@$R6=M?'W9VM[*Y<E53L+N_".5I@P!)
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M9VPP(#%\QZF2YM(0?W+Z&U*GSOMX3-,I<!W\E[#_Y-@S3?0WX^W+L%:P@&X
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MG5;N:<(-(CBV?(XB ?!OK0\GQAC79\3%">]NFW.7A\Q@;I!@AR".D7H]H;T
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MI_#:* [)R7CI4B7$'U]IR7H0,M H"Z;8P62F2D@![.=N1<XRF-$#3(@ES./
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MVSQ%CO^0YWW.A#Z;'O X("P6RBO880 0EJ^#W2?K]PE3 </*WY7 *C&H; K
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M?RAQ7REY&66AA-["$(;-<1^JALP+SR,J1/F<8Z%^WC6.>AF(;( /^G].HQ5
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MFH:SEX*-'\H1$H-$BAJ[Z'>'8W0W"(6Y DQFG/CK^E:/0>[KL:#'GOV/8-R
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M2EXRJN2Y]<; U[;9+&3K6GX9II7M& [I?.P1T]+K /@:RGU5 %M4 .<Q6%/
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M^O1,)WQKZL"_0< QVWJIM@@6LAD'H MD"$H>=$$4JRC_.)4*"K N<B;Q:O)
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M0OQPOU"!.2?Z7,E([2H$4<92>0#J=YH4[%1Z0E:K=994-]&Y4GFCIIZ21N/
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M0(4#BX:(+CC";G5$0NK9!4%U*ZJ:>_!@GJD^I#6A,IF 4,!I4V0/?$I!%59
M6STAQ>9 (QC%A4/5H8Y 63>3P=LO<W#FB2%A,F>21!!F+IG'R^_I)KIC!<#
M@QHFB7(9EB4=7(JAF%U<CA6_;9=D23X3K4@T]^!!#6.12'M2X:OSKE*]0D.U
MWLW!.?O$W]I:-R756TYG_P-02P,$%     @ H3H(691'GK+?!0  ]SX  !4
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M<EH]<<KBRERI/!,R7I<D%W.5>N0X[LW88YA@(C2.AO*#+'M8EBR^_'O.Q"7
M:)(7',6%SI1*;<XZUIA@*"LR8N&;$]7+]" R&CQM(46S&JJRW-9QQ*N,$8]U
M)O&Q(F+]=*T0X0)QD:\;STGZK/^4L\RUDLQ+?9O>25#)$!0LJ(YD/,'\K-.7
M5W%BX!1SKG8Q#^^2=+J]'[ZE@"/!-I&,+U,T,Q2TQM0Z&#%X&OK(-XAH#%4J
M#@"KJ&WW?,[\+ [FCOW1BC%V3 ,#3]TVQ;3<58T42NWH':A]2?(8I7]CQ"_%
MEMRAMP-E*%Y#P=7<7U!+U6M)E.[#=Z/[QK?-REMP5NTK..CJNXO:2?]*&N6
M \ .V%R*7I(47R^S">:&\*ZP6IIZ&)[,#24TJ%L?K43] %[4.SPCLA!:7*/,
M/'?[(!5Q30A4@;VEM!+9S*"$/@0O]+DHC:-T+.Y'UU_QDU5I!Z8B=0T#56M_
M,:W$KJ50:O\&7NTQC1E?,%[6=R_*Q.=L*8IY.F>)?2]O-:+BA(814'VQ2Z&M
M7-*04'GF"+QG'M!ZG(AJR91L?E3QG.P;L!6?.+%0'=*NN%;><*92KC@&[XI1
MDHA"<_5V12@>6!WAP57<8,5!=4)S4:U<8$VC^SN0VW0N^E%+"T0M+1"])PN8
M17VG!:(7"T#N\;GH#UM:8-C2 L/W9 &SJ.^TP/#% I ;?Q7ZY^+C#7]@*^HS
M0!UEDW\;!5Q\9T&[2+^=1 L/N?-7(5]>V=[P6\X>R>8I'*?Z#JC- C4H<!_X
M2]O%#+5,VA'P.X':SIO;'.]QH JQ'@0T!+CR]E)VVOUU!JTT_/:@8G[+\@*E
M_Y"%LWW@ ]I4-X# M?>5M8L#C#S:!Y"[A_*<->(8692WA?03(940/'4]U!OT
MK([4"D+N",IG9-/;.:/V7V]<8;4<]3 \-1M*:%"T/EJK"KEG=X_C)1=>'$23
M!UFFH:HKK):D'H:G:D,)#:K61VM5(??<'CB2S]S?/V43EAJ26F-J,8P8/#%]
MY!N4-(;J)V4@]\VN686TY2$W#T*MBA4!3]CF0AKDM2;0(D/NC.DCS,4ZGB,Z
MPY8?T'T0XTA<A<#3N44I+8_(U0Q::?@-L(L,\YGPZ1?.5L7\G&4+1.TWOUYD
MY6[(@80G?_O"6MT/.1)I,T!NBOTI/%Q@*CAG2ZI^U3,?A?-BU#HY,/"D;U-,
M@^B.%%INR!VO>Y:2F!3"J]]0@3E!YF69&Z"/\!8 /)4;RV@ZNEO&:WTA][EN
M.9:VQ#3&Y3\HY!]V^,UT6KM/;@:JA?(!X>G>NJP&_7UYM \@][D,_N,\7V+>
MV@U.N-T3%CAX9S25N)L_+-FT2_;MI9V&M26\$AODG\\W$?DB_ZS]\7]02P$"
M% ,4    " "A.@A9 AN_R@Y,  "5^@, %0              @ $     968R
M,# S,S<X.2UE>#DY+3$N:'1M4$L! A0#%     @ H3H(62V6T:G#$P  ,XD
M !$              ( !04P  &5F,C P,S,W.#E?.&LN:'1M4$L! A0#%
M  @ H3H(640_66E) P  0@\  !$              ( !,V   &EM8W(M,C R
M-# X,#@N>'-D4$L! A0#%     @ H3H(67I>/:%["   ,%8  !4
M     ( !JV,  &EM8W(M,C R-# X,#A?;&%B+GAM;%!+ 0(4 Q0    ( *$Z
M"%F41YZRWP4  /<^   5              "  5EL  !I;6-R+3(P,C0P.# X
>7W!R92YX;6Q02P4&      4 !0!' 0  :W(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ef20033789_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="imcr-20240808.xsd" xlink:type="simple"/>
    <context id="c20240808to20240808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671927</identifier>
        </entity>
        <period>
            <startDate>2024-08-08</startDate>
            <endDate>2024-08-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20240808to20240808"
      id="Fact_9182d3cddd904cf98e39820bbb07a112">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20240808to20240808"
      id="Fact_bd98693d0b7c4e30860edbad8272d2d1">0001671927</dei:EntityCentralIndexKey>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240808to20240808"
      id="Fact_e50e23c8fe0f4bfebb8babfb04b35d3e">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:DocumentType
      contextRef="c20240808to20240808"
      id="Fact_5f88e26441fd4e7f8c0dee7bcf19d430">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20240808to20240808"
      id="Fact_1d1db6e510014e1e8cffec9223f83b08">2024-08-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20240808to20240808"
      id="Fact_c9200b9e712b4941aa48ed5ed31febd0">Immunocore Holdings plc</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240808to20240808"
      id="Fact_e2ee9f77ec844cb4837a0d2b990c4822">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20240808to20240808"
      id="Fact_7c6b857bba974b52ab156471d5f3b988">001-39992</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240808to20240808"
      id="Fact_5d89465973714ad48ac5100d18649163">92 Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20240808to20240808"
      id="Fact_7178df4025804e72a22f647d2b2e8fa0">Milton Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="c20240808to20240808"
      id="Fact_94fc2fea0902488489b8f628339812e8">Abingdon</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="c20240808to20240808"
      id="Fact_eb44ec49a58f4390af79d1faf41cbf14">Oxfordshire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="c20240808to20240808"
      id="Fact_d2ef7854c3a14a2fa3b9730099c77d5a">GB</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240808to20240808"
      id="Fact_36c3b00f7cbb491a84fda88136952c40">OX14 4RY</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240808to20240808"
      id="Fact_b5a8419cb3084866a7f8bc5f0ff7832d">44</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240808to20240808"
      id="Fact_00cd578201274fd09ae5c2b1d71c68b4">1235 438600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20240808to20240808"
      id="Fact_0251b943961642c0808f70d74047ec12">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20240808to20240808"
      id="Fact_5030b042c9e84672bb8f3adee8b0bbda">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20240808to20240808"
      id="Fact_c2a01de1cd694081bdcb96c662a4f20e">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20240808to20240808"
      id="Fact_484cf9a4fbee425d82adcea86ac8e104">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20240808to20240808"
      id="Fact_76a07c9d81df49b2af396cc30862c718">American Depositary Shares, each representing one ordinary share, nominal value &#xa3;0.002 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240808to20240808"
      id="Fact_1fdc6342bec147dfbe1a3087faba9c11">IMCR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240808to20240808"
      id="Fact_3a911b3b84df42f199e0aa19ded07235">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240808to20240808"
      id="Fact_f0c18f62725440688595266df8604f02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
